Singapore markets close in 44 minutes

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
45.80-0.31 (-0.67%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 52.7B
Enterprise value 31.13B
Trailing P/E 1.94
Forward P/E 1-6.35
PEG Ratio (5 yr expected) 10.04
Price/sales (ttm)13.29
Price/book (mrq)1.59
Enterprise value/revenue 35.56
Enterprise value/EBITDA 7-3.55

Trading information

Stock price history

Beta (5Y monthly) 1.57
52-week change 319.89%
S&P500 52-week change 334.98%
52-week high 362.16
52-week low 332.47
50-day moving average 345.17
200-day moving average 352.07

Share statistics

Avg vol (3-month) 3760.25k
Avg vol (10-day) 3356.41k
Shares outstanding 558.95M
Implied shares outstanding 6N/A
Float 58.24M
% held by insiders 11.23%
% held by institutions 1113.41%
Shares short (30 Aug 2021) 45.64M
Short ratio (30 Aug 2021) 49.69
Short % of float (30 Aug 2021) 415.78%
Short % of shares outstanding (30 Aug 2021) 49.56%
Shares short (prior month 29 Jul 2021) 44.81M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021


Profit margin 783.22%
Operating margin (ttm)-161.57%

Management effectiveness

Return on assets (ttm)-14.40%
Return on equity (ttm)-29.42%

Income statement

Revenue (ttm)203.2M
Revenue per share (ttm)3.02
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)-167.08M
EBITDA -318.37M
Net income avi to common (ttm)-335.45M
Diluted EPS (ttm)23.67
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.67B
Total cash per share (mrq)28.38
Total debt (mrq)101.91M
Total debt/equity (mrq)5.92
Current ratio (mrq)28.07
Book value per share (mrq)28.74

Cash flow statement

Operating cash flow (ttm)-355.65M
Levered free cash flow (ttm)-122.5M